INNOVATE Corp. 8-K

What Happened
INNOVATE Corp. (VATE) announced on March 31, 2026 that its MediBeacon® Transdermal GFR Monitor and Reusable Sensor received CE Mark approval under the European Medical Device Regulation (MDR). The company filed a Current Report on Form 8-K the same day and attached a press release as Exhibit 99.1.

Key Details

• Event: CE Mark clearance for MediBeacon Transdermal GFR Monitor and Reusable Sensor under EU MDR.
• Filing: Form 8-K filed March 31, 2026; press release attached as Exhibit 99.1 (the exhibit is furnished, not filed, for Section 18 purposes).
• Company ticker: INNOVATE Corp. (VATE).
• Administrative: Form 8-K signed by Michael J. Sena, Chief Financial Officer.

Why It Matters
CE Mark under MDR permits the company to market the MediBeacon transdermal GFR monitor and reusable sensor in the European Economic Area, clearing a key regulatory step for commercialization in Europe. For investors, this is a material regulatory milestone that could enable revenue growth in the EU once launch, distribution, and reimbursement arrangements are in place. The filing does not include financial results or launch timing—investors should watch for follow-up updates on commercialization plans, pricing, and sales guidance.